ArticleJournal of nanobiotechnology2026
Precision mitochondrial delivery for tissue repair in intervertebral disc degeneration.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aims to develop a pathological microenvironment-responsive hydrogel system leveraging AMP-activated protein kinase (AMPK) activation and mitochondrial delivery to regulate mitochondrial function, mitigate oxidative stress, and inhibit ferroptosis in nucleus pulposus cells (NPCs) for microenvironmental remodeling and tissue repair in intervertebral disc degeneration (IVDD). Bulk RNA Sequencing (RNA-seq) on nucleus pulposus (NP) tissues from Sham and IVDD rats, intersected with tert-butyl hydroperoxide (TBHP)-treated NPCs, identified key regulatory pathways. Treatment with AMPK modulators, A-769,662 and EX229, systematically evaluated AMPK's regulatory impact on mitochondrial function and ferroptosis. FoxO3a interference via small hairpin RNA, coupled with molecular analyses, elucidated downstream targets and mechanisms. Mitochondria-derived microvesicles loaded with A-769,662, encapsulated in phenylboronic acid-modified gelatin hydrogel (GPVA), demonstrated enhanced mitochondrial function and efficient drug release behavior. In IVDD animal models, GPVA hydrogels significantly improved tissue structure, mitochondrial function, and mitigated oxidative stress and ferroptosis, with FoxO3a knockdown confirming the significance of AMPK-FoxO3a axis. This novel ROS/pH-responsive injectable hydrogel system offers precision delivery of mitochondrial therapy, effectively enhancing NPC function, promoting tissue repair, and showing promising translational potential for IVDD treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.